Former partner aims to extend Amyris bankruptcy before it toggles to a sale


The company faces a creditor's deadline of mid-September to restructure or face the sale of most of its assets.

Previous Lab Notes: Verrica throws support behind FDA crackdown; Janssen drug targeted for Medicare price negotiations
Next Done deal: Globus Medical, NuVasive complete $3B merger